🔴 Breaking
Big Pharma’s patent cliff sparks biotech deal rush • Real Estate ETFs Beat Market Despite Rising Rates • Investors flock to ETFs over mutual funds • Easing Conflict Boosts Trade as Fed, Liquidity Risks Loom • Liquids Pipelines Face Another Rate Hike in July • Dimensional broadens fixed income share class offerings • Treasury yields seen steady through 2026 • Global Markets Track Key Trends June 29 • What you don’t know about debt management software • Discovering Pafikotatambua.org: An Engaging Digital Hub Big Pharma’s patent cliff sparks biotech deal rush • Real Estate ETFs Beat Market Despite Rising Rates • Investors flock to ETFs over mutual funds • Easing Conflict Boosts Trade as Fed, Liquidity Risks Loom • Liquids Pipelines Face Another Rate Hike in July • Dimensional broadens fixed income share class offerings • Treasury yields seen steady through 2026 • Global Markets Track Key Trends June 29 • What you don’t know about debt management software • Discovering Pafikotatambua.org: An Engaging Digital Hub
Tuesday, July 14, 2026

Tag

biotech

Big Pharma’s patent cliff sparks biotech deal rush
Scale Steps

Big Pharma’s patent cliff sparks biotech deal rush

Big Pharma's $300 billion patent cliff is driving a biotech deal rush as drugmakers scramble to buy new pipelines. Discover the strategy behind the surge.

Cecily Ravenswood · 3 hours ago
Read More →